Sponsor

Kirby Institute

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Kirby Institute appears in 61 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials61
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Swabs in Screening for HPV (SWISH)NCT07790601 · lead sponsor · 2026-11-01
NOT_YET_RECRUITING
Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)NCT06317051 · lead sponsor · 2024-12-16
ACTIVE_NOT_RECRUITING
Australian Hepatitis and Risk Survey in PrisonsNCT05839522 · lead sponsor · 2022-04-27
UNKNOWN
Inflammation and Co-Infections in D²EFTNCT04183738 · lead sponsor · 2021-02-01
WITHDRAWN
COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited SettingsNCT04371835 · lead sponsor · 2020-08-12
COMPLETED
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)NCT04354818 · lead sponsor · 2020-05-11
UNKNOWN
Body Composition Sub-study of the D2EFT TrialNCT03675815 · lead sponsor · 2019-12-05
COMPLETED
Simplified Monitoring Myanmar SM2 StudyNCT04113629 · lead sponsor · 2019-01-22
COMPLETED
Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE)NCT04641013 · lead sponsor · 2017-12-05
ACTIVE_NOT_RECRUITING
Dolutegravir and Darunavir Evaluation in Adults Failing TherapyNCT03017872 · lead sponsor · 2017-11-23
UNKNOWN
Western Australian Pre-exposure Prophylaxis for HIV Implementation TrialNCT03327155 · lead sponsor · 2017-11-16
COMPLETED
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.NCT02625909 · lead sponsor · 2017-03-09
COMPLETED
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/PNCT02634008 · lead sponsor · 2016-06-01
COMPLETED
Expanded PrEP Implementation in Communities in NSWNCT02870790 · lead sponsor · 2016-03-01
COMPLETED
Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation EndpointsNCT02394730 · lead sponsor · 2015-09-01
COMPLETED
PrEP Demonstration Project (PRELUDE Study)NCT02206555 · lead sponsor · 2014-11-14
COMPLETED
Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected PatientsNCT02732457 · lead sponsor · 2014-09-01
TERMINATED
Control and Elimination Within Australia of Hepatitis C From People Living With HIVNCT02102451 · lead sponsor · 2014-07-01
UNKNOWN
MARCH Renal SubstudyNCT01637259 · lead sponsor · 2012-06-01
COMPLETED
MARCH Central Nervous System SubstudyNCT01637233 · lead sponsor · 2012-06-01
COMPLETED
The Neurocognitive Sub-study of Encore1NCT01516060 · lead sponsor · 2012-01-01
COMPLETED
The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)NCT01271894 · lead sponsor · 2011-09-01
COMPLETED
The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1NCT01451333 · lead sponsor · 2011-09-01
COMPLETED
Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.NCT01011413 · lead sponsor · 2011-08-01
COMPLETED
Maraviroc Switch Collaborative StudyNCT01384682 · lead sponsor · 2011-08-01
COMPLETED
Study of the Prevention of Anal CancerNCT02007421 · lead sponsor · 2010-09-10
COMPLETED
A Study to Explore Reconstitution of Immunity in Patients With Advanced HIV-1-infectionNCT01296373 · lead sponsor · 2010-09-01
COMPLETED
Bone and Body Comp: A Sub Study of the SECOND-LINE StudyNCT01513122 · lead sponsor · 2010-02-01
COMPLETED
Pharmacokinetics of Lamivudine at Two Different DosesNCT00985647 · lead sponsor · 2009-12-01
COMPLETED
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.NCT00985543 · lead sponsor · 2009-10-01
COMPLETED
A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line RegimenNCT00931463 · lead sponsor · 2009-09-01
COMPLETED
Raltegravir and Atazanavir Dosing Strategy StudyNCT00874523 · lead sponsor · 2009-07-01
COMPLETED
Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell ResponseNCT00772590 · lead sponsor · 2009-03-01
COMPLETED
The Effect of Raltegravir on HIV Decay During Primary and Chronic InfectionNCT00641641 · lead sponsor · 2008-03-01
COMPLETED
Thai Prophylactic HIV Vaccine Phase I StudyNCT00333424 · lead sponsor · 2007-08-01
TERMINATED
ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial RegimensNCT00335322 · lead sponsor · 2007-02-01
COMPLETED
A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL StudyNCT00192634 · lead sponsor · 2005-12-01
COMPLETED
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial LipoatrophyNCT00126308 · lead sponsor · 2005-11-01
TERMINATED
Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 SubstudyNCT00147355 · lead sponsor · 2005-11-01
TERMINATED
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy SubjectsNCT00192621 · lead sponsor · 2004-11-01
COMPLETED
A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 StudyNCT00192608 · lead sponsor · 2004-11-01
COMPLETED
Tenofovir in HIV/HBV CoinfectionNCT00192595 · lead sponsor · 2004-01-01
COMPLETED
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)NCT00192660 · lead sponsor · 2003-02-01
COMPLETED
ITV Extension StudyNCT00332930 · lead sponsor · 2002-09-01
COMPLETED
Pravastatin for Hyperlipidaemia in HIV.NCT00227500 · lead sponsor · 2001-07-01
COMPLETED
Can Resistance Enhance Selection of Treatment? (CREST)NCT00262717 · lead sponsor · 2001-03-01
COMPLETED
Enhancing Uptake of Needle and Syringe Programs in Canadian Federal PrisonsNCT07122219 · collaborator · 2024-10-01
RECRUITING
Combating Related Epidemics in HCVNCT07560046 · collaborator · 2026-08-01
NOT_YET_RECRUITING
MENJAGA: Continuous Quality Improvement for Antenatal HIV, Syphilis and Hepatitis B Testing in IndonesiaNCT06058286 · collaborator · 2023-10-01
UNKNOWN
HIV Awal (Early) Testing & Treatment Indonesia Project Intervention PhaseNCT03659253 · collaborator · 2017-11-22
COMPLETED
HIV Awal (Early) Testing & Treatment Indonesia Project Observational PhaseNCT03429842 · collaborator · 2015-09-15
COMPLETED
HCV Treatment in HIV Co-Infected Patients in AsiaNCT01838772 · collaborator · 2013-12-01
COMPLETED
Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)NCT01159223 · collaborator · 2011-05-01
COMPLETED
Second-line TherapyNCT01788891 · collaborator · 2011-01-01
COMPLETED
Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) ValidationNCT01138241 · collaborator · 2010-03-01
COMPLETED
Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)NCT01138267 · collaborator · 2009-05-01
COMPLETED
Strategic Timing of Antiretroviral TreatmentNCT00867048 · collaborator · 2009-04-15
COMPLETED
Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral TherapyNCT00511056 · collaborator · 2007-09-01
COMPLETED
HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infectionNCT00476723 · collaborator · 2005-04-01
COMPLETED
The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected PatientsNCT00400738 · collaborator · 2004-03-01
COMPLETED

Drugs studied in this sponsor's trials

32 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Kirby Institute as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
efavirenz3
raltegravir3
ritonavir3
darunavir2
dolutegravir2
lopinavir / ritonavir2
placebo2
tenofovir2
efavirenz RxCUI 195085 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials raltegravir RxCUI 719872 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials ritonavir RxCUI 85762 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials darunavir RxCUI 460132 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials dolutegravir RxCUI 1433868 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials lopinavir / ritonavir RxCUI 284640 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials placebo RxCUI 8375 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials tenofovir RxCUI 117466 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials abacavir RxCUI 190521 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial amprenavir RxCUI 228656 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dapagliflozin 10 MG Oral Tablet RxCUI 1488569 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dasabuvir RxCUI 1597381 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial didanosine RxCUI 3364 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dolutegravir 50 MG Oral Tablet RxCUI 1433873 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ezetimibe / rosuvastatin RxCUI 2535748 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial glecaprevir / pibrentasvir RxCUI 1940702 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial indinavir RxCUI 114289 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lamivudine RxCUI 68244 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lamivudine 300 MG Oral Tablet RxCUI 349491 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial maraviroc RxCUI 620216 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial nelfinavir RxCUI 134527 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial nevirapine RxCUI 53654 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pitavastatin calcium 4 MG Oral Tablet RxCUI 861652 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pravastatin RxCUI 42463 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor46
collaborator15
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.